Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris.Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients.This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.

Biotechnology

Pharmaceutical

Therapeutics

Invectys Therapeutics

Jake Kushner

Alix Jacquier

Justine Heidrich

Melissa Yang

Rosemary Williams

Julien Caumartin

The Scientific and Research Team at Invectys Therapeutics is dedicated to the exploration, development, and implementation of groundbreaking immunotherapy treatments for cancer. This team of experts, including advisors, research scientists, and program managers, focuses on understanding and mobilizing the immune system's anti-tumor responses, specifically targeting tumor antigens such as telomerase and HLA-G. Their collective efforts aim to advance preclinical development and innovate therapeutic strategies to treat a wide range of cancers.

Scientific and Research Team

Leadership Team

Vice Presidents & Heads

Scientific and Research Team

About

Team members

Other teams at Invectys Therapeutics

Leadership Team

Vice Presidents & Heads